Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT06645691
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 2
- Enrolled
- 200 participants
- Registry
-
NCT06645691
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Singapore
- Registry status
- Recruiting
Technical summary
Registry record NCT06645691. Allocation not applicable; no masking; primary purpose diagnostic. Start 2024-10-17 (actual); primary completion 2028-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Hyperpolarized MR Imaging With Carbon-13 Pyruvate in the Human Body
- Acronym
- POLARIC-13
- Condition
- Heart Failure
- Condition
- Cardiometabolic Syndrome
- Condition
- Cancer Diagnosis
- Condition
- Cardiovascular Diseases
- Condition
- Healthy Volunteers
- Intervention (Drug)
- Hyperpolarized 13C-pyruvate
- Lead sponsor
- National Heart Centre Singapore
- Collaborator
- National Medical Research Council (NMRC), Singapore
Record details
- Record id
cardio:ct-nct06645691- Content hash
4179fe9b1ab46cdfe6deee90bbf0f902ed38645b0f89bdc65d6a14bc8441c48f